Abstract
The aim of the experiment was to study the anti-inflammatory effect of the novogalene agent Ledum 50, obtained from Ledum palustre shoots, in a rat model of acute bronchitis.
Materials and methods. Acute bronchitis was initiated by endotracheal administration of 1 % formalin solution. The effectiveness of Ledum 50 was investigated by the number of leukocytes and cell composition in isotonic BAL solution after 24 hours and after 8 days of the experiment. Serum levels of C-reactive protein (CRP), alkaline phosphatase (AP) and CIC were determined. Histological examination of the lungs was carried out.
Results. Endotracheal injection of formalin caused irritation of the trachea and bronchi, excessive formation of bronchial secretions (heavy breathing, wheezing) in all the studied groups. The lethality of animals in the OB group on the 3rd day of the experiment (1 rat) was recorded, in the studied groups there was no death. The level of leukocytes in BAL after 24 hours exceeded the index of the IC group by 9.63 times (p<0.05), after 8 days – by 3.0 times (p<0.05). In the cellular composition of BAL, there was a significant increase in granulocytes (rod- and segmented neutrophils, eosinophils), monocytes and a decrease in the lymphocyte population against the IC group. Such changes were verified in the long term (8 days of the experiment), which indicates an inflammatory process.
In the group of rats that received Ledum 50, leukocytes in the BAL significantly decreased, the number of monocytes and lymphocytes in the BAL decreased, the amount of CIC in the blood serum, CRP and AP normalized. In terms of effectiveness, Ledum 50 significantly exceeded the BAL values of the reference drug. The effectiveness of experimental therapy for acute bronchitis was also verified by studying the histostructure of the airways and the respiratory part of the lungs.
Conclusions. Studies confirm the favorable course of acute bronchitis with Ledum 50 monotherapy. This fact is confirmed by the results of normalization of hematological parameters, leukocytes and BAL cell composition after 7 days of treatment with the claimed agent. This is the basis for further preclinical and clinical studies with the aim of creating an oral drug for the treatment of acute bronchitis.
Reference37 articles.
1. Graham, W. (2018). Acute bronchitis. Can Fam Physician, 54, 238–239.
2. Sanjay, S. (2020). Acute Bronchitis. Available at: https://www.msdmanuals.com/professional/pulmonary-disorders/acute-bronchitis/acute-bronchitis
3. Unyfykovanyi klinichnyi protokol pervynnoi medychnoi dopomohy. «Kashel u doroslykh». Available at: https://kiai.com.ua/ua/archive/2016/3%2892%29/pages-38-45/unifikovaniy-klinichniy-protokol-pervinnoyi-medichnoyi-dopomogi-kashel-u-doroslih-
4. Nastanovy na zasadakh dokazovoi medytsyny. Nastanova 00129. Available at: https://guidelines.moz.gov.ua/documents/3030
5. Kemmerich, B., Eberhardt, R., Stammer, H. (2011). Efficacy and Tolerability of a Fluid Extract Combination of Thyme Herb and Ivy Leaves and Matched Placebo in Adults Suffering from Acute Bronchitis with Productive Cough. Arzneimittelforschung, 56 (9), 652–660. doi: http://doi.org/10.1055/s-0031-1296767